Literature DB >> 4629260

Response of mice to injection of ribosomal fraction from group B Neisseria meningitidis.

D W Thomas, E Weiss.   

Abstract

Ribosomes of strain NOR-7 of group B Neisseria meningitidis were isolated by a procedure that included treatment of the cells with sodium dodecyl sulfate, disruption in a French pressure cell, and differential centrifugation. These preparations consisted of 66% ribonucleic acid and 24% protein and sedimented as a single component with a constant of approximately 66S. When used in immunodiffusion tests with homologous rabbit antiserum, untreated ribosomes formed two precipitin lines, when treated with ribonuclease three lines, and when Pronase-digested only one distinct line. Qualitatively indistinguishable reactions were obtained with the same antiserum and ribosomes from group A meningococci, but no precipitation occurred with those of Escherichia coli. When injected into mice, group B ribosomes elicited an increase in the number of antibody-producing spleen cells demonstrable by the hemolytic plaque technique using unsensitized sheep erythrocytes. Sensitization of the erythrocytes with increasing amounts of supernatant fluid of meningococcal cultures progressively reduced the number of demonstrable plaque-forming cells. Neuraminidase treatment of the erythrocytes increased immune hemolysis, whereas Pronase digestion reduced it. Injected mice were protected against homologous and heterologous meningococcal challenge. Both hemolysis and protection-inducing activities of the ribosomes were unimpaired by ribonuclease, but were reduced by Pronase. It is concluded that the immunological response elicited by the meningococcal ribosomes does not involve the group-specific carbohydrate antigen. The immunological mechanism by which the mice are protected against meningococcal challenge remains unknown.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4629260      PMCID: PMC422541          DOI: 10.1128/iai.6.3.355-363.1972

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  The influenza virus neuraminidase.

Authors:  A GOTTSCHALK
Journal:  Nature       Date:  1958-02-08       Impact factor: 49.962

Review 2.  Biodynamic effects of oligonucleotides.

Authors:  W Braun; W Firshein
Journal:  Bacteriol Rev       Date:  1967-06

3.  Recent studies on acquired immunity in tuberculosis.

Authors:  G P Youmans; A S Youmans
Journal:  Curr Top Microbiol Immunol       Date:  1969       Impact factor: 4.291

4.  Antibody production studied by means of the LHG assay. I. The splenic response of CBA mice to sheep erythrocytes.

Authors:  H H Wortis; R B Taylor; D W Dresser
Journal:  Immunology       Date:  1966-12       Impact factor: 7.397

5.  Cell-mediated resistance induced with immunogenic preparations of Salmonella typhimurium.

Authors:  M R Venneman; L J Berry
Journal:  Infect Immun       Date:  1971-10       Impact factor: 3.441

6.  Serum-mediated resistance induced with immunogenic preparations of Salmonella typhimurium.

Authors:  M R Venneman; L J Berry
Journal:  Infect Immun       Date:  1971-10       Impact factor: 3.441

7.  Isolation and partial characterization of an immunogenic moiety obtained from Salmonella typhimurium.

Authors:  M R Venneman; N J Bigley
Journal:  J Bacteriol       Date:  1969-10       Impact factor: 3.490

8.  Utilization of neuraminic acid receptors by mycoplasmas.

Authors:  R J Manchee; D Taylor-Robinson
Journal:  J Bacteriol       Date:  1969-06       Impact factor: 3.490

9.  Detection of Antibody-Producing Cells of Mice Injected with Antigens of Neisseria meningitidis.

Authors:  D G Evans
Journal:  Infect Immun       Date:  1970-02       Impact factor: 3.441

10.  Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  25 in total

1.  Evidence for an extrinsic immunogen in effective ribosomal vaccines from Salmonella typhimurium.

Authors:  P Hoops; N E Prather; J Berry; J M Ravel
Journal:  Infect Immun       Date:  1976-04       Impact factor: 3.441

2.  Humoral immunity to Streptococcus pneumoniae induced by a pneumococcal ribosomal protein fraction.

Authors:  C L Swendsen; W Johnson
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

3.  Immuno-stimulation by a ribosomal vaccine associated with a bacterial cell wall adjuvant in humans.

Authors:  F B Michel; L Dussourd D'Hinterland; J Bousquet; A M Pinel; G Normier
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

4.  Brucella ribosomal protein L7/L12 is a major component in the antigenicity of brucellin INRA for delayed-type hypersensitivity in brucella-sensitized guinea pigs.

Authors:  G Bachrach; M Banai; S Bardenstein; G Hoida; A Genizi; H Bercovier
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

5.  Ribosomal vaccines. II. Specificity of the immune response to ribosomal ribonucleic acid and protein isolated from Salmonella typhimurium.

Authors:  W Johnson
Journal:  Infect Immun       Date:  1973-09       Impact factor: 3.441

6.  The immunogenic activity of ribosomal fractions derived from Brucella abortus.

Authors:  M J Corbel
Journal:  J Hyg (Lond)       Date:  1976-02

7.  Immunogenicity of ribosomal vaccines isolated from group A, type 14 Streptococcus pyogenes.

Authors:  W O Schalla; W Johnson
Journal:  Infect Immun       Date:  1975-06       Impact factor: 3.441

8.  Capsular serotypic specificity of the protection conferred on mice by Klebsiella pneumoniae ribosomal preparations.

Authors:  M Riottot; J M Fournier; J Pillot
Journal:  Infect Immun       Date:  1979-05       Impact factor: 3.441

9.  Immunogenic activity of a ribosomal fraction obtained from Pasteurella multocida.

Authors:  T Baba
Journal:  Infect Immun       Date:  1977-01       Impact factor: 3.441

10.  Variability of protection in inbred mice induced by a ribosomal vaccine prepared from Salmonella typhimurium.

Authors:  M L Misfeldt; W Johnson
Journal:  Infect Immun       Date:  1976-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.